公开(公告)号：US20190248920A1

公开(公告)日：2019-08-15

申请号：US16333407

申请日：2017-09-22

申请人： CSL LIMITED

发明人： Peter SCHMIDT ,  Chao-Guang CHEN ,  Con PANOUSIS ,  Louis FABRI

IPC分类号： C07K16/36 ,  A61P7/02

CPC分类号： C07K16/36 ,  A61K38/00 ,  A61K2039/505 ,  A61P7/02 ,  C07K14/4721 ,  C07K2317/31 ,  C07K2317/76 ,  C07K2319/035

摘要： A membrane targeted binding protein that binds to at least one blood coagulation factor, wherein the binding protein has pro-coagulant activity.

公开(公告)号：US20190247304A1

公开(公告)日：2019-08-15

申请号：US16396272

申请日：2019-04-26

申请人： OTITOPIC INC.

发明人： Kambiz YADIDI

IPC分类号： A61K9/00 ,  A61K31/616 ,  A61M15/00

CPC分类号： A61K9/0075 ,  A61K9/14 ,  A61K31/616 ,  A61M15/0045 ,  A61M2202/064 ,  A61P7/02 ,  Y10S514/958 ,  Y10T428/2982

摘要： The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.

公开(公告)号：US20190192432A1

公开(公告)日：2019-06-27

申请号：US16286898

申请日：2019-02-27

申请人： Clemson University Research Foundation

发明人： Jeoung Soo Lee

IPC分类号： A61K9/107 ,  A61K9/51 ,  A61K47/69 ,  A61K47/59 ,  A61K45/06 ,  A61P7/02 ,  A61P9/00

CPC分类号： A61K47/488 ,  A61K9/1075 ,  A61K9/5153 ,  A61K31/4015 ,  A61K31/713 ,  A61K45/06 ,  A61K47/482 ,  A61K47/48561 ,  A61K47/593 ,  A61K47/6907 ,  A61K47/6937 ,  A61P7/02 ,  A61P9/00 ,  B82Y5/00 ,  C07K16/2863 ,  C12N15/113

摘要： Provided herein are multi-functional particles. The particles may include poly(lactide-co-glycolide)-g-polyethylenimine (PLGA-g-PEI (PgP)), at least one targeting moiety, at least one therapeutic agent, and/or at least one nucleic acid. Also provided herein are methods of using the multi-functional particles.

公开(公告)号：US20180326024A1

公开(公告)日：2018-11-15

申请号：US15978394

申请日：2018-05-14

申请人： University Hospital Ostrava

发明人： Vaclav Prochazka ,  Jaromir Gumulec ,  Jirka Macák ,  Adéla Vrtková

IPC分类号： A61K38/48 ,  A61K9/00 ,  A61P7/02

CPC分类号： A61K38/4886 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/36 ,  A61P7/02 ,  C12Y304/24087

摘要： This document relates to materials and methods for treating and/or preventing an embolism (e.g., a cerebral embolism). For example, methods for using a composition including a disintegrin and metalloprotease with thrombospondin motif repeats (ADAMTS) polypeptide to treat a mammal having an embolism (e.g., a cerebral embolism) are provided.

公开(公告)号：US20180201603A1

公开(公告)日：2018-07-19

申请号：US15918195

申请日：2018-03-12

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Michael J. Orwat ,  Donald J. P. Pinto ,  Leon M. Smith, II ,  Shefali Srivastava

IPC分类号： C07D401/14 ,  C07D491/113 ,  A61K31/4725 ,  C07D491/10 ,  C07D487/10 ,  C07D487/08 ,  C07D487/04 ,  C07D471/10 ,  C07D413/14 ,  C07D401/10 ,  C07D401/04 ,  C07D217/26 ,  C07D491/107 ,  A61K31/551 ,  A61K31/55 ,  A61K31/541 ,  A61K31/5377 ,  A61K31/496

CPC分类号： C07D401/14 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61P7/02 ,  C07B2200/13 ,  C07D217/26 ,  C07D401/04 ,  C07D401/10 ,  C07D413/14 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/10 ,  C07D491/107 ,  C07D491/113

摘要： The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

公开(公告)号：US20180161305A1

公开(公告)日：2018-06-14

申请号：US15580933

申请日：2015-09-23

申请人： INSTITUTO TECNOLOGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY

发明人： Carmen HERNANDEZ BRENES ,  Gerardo de Jesus GARCIA RIVAS ,  Guillermo TORRE AMIONE ,  Dariana Graciela RODRIGUEZ SANCHEZ

IPC分类号： A61K31/365 ,  A61P7/02

CPC分类号： A61K31/365 ,  A61K2300/00 ,  A61P7/02

摘要： The present disclosure relates, according to some embodiments, to acetogenin molecules that may have antiplatelet and/or antithronibic activities. In some embodiments, the present disclosure relates to an acetogenin molecule selected from the group comprising: Acetogenin 1, Acetogenin 2, Acetogenin 3, Acetogenin 4, Acetogenin 5, Acetogenin 6, Acetogenin 7, Acetogenin 8, Acetogenin 9, Acetogenin 10, Acetogenin 11, Acetogenin 12, Acetogenin 13, and Acetogenin 14. The present disclosure relates in some embodiments to a pharmaceutical composition comprising a first acetogenin molecule and a delivery vehicle, wherein the first acetogenin molecule is selected from the group comprising: Acetogenin 1, Acetogenin 2, Acetogenin 3, Acetogenin 4, Acetogenin 5, Acetogenin 6, Acetogenin 7, Acetogenin 8, Acetogenin 9, Acetogenin 10, Acetogenin 11, Acetogenin 12, Acetogenin 13, and Acetogenin 14.

公开(公告)号：US20180142036A1

公开(公告)日：2018-05-24

申请号：US15570511

申请日：2016-05-06

申请人： Laboratoire Francais du Fractionnement et des Biotechnologies

发明人： Abdessatar Sami CHTOUROU

IPC分类号： C07K16/34 ,  A61K38/36 ,  C07K16/06 ,  A61P37/00 ,  A61P35/00 ,  A61P7/02

CPC分类号： C07K16/34 ,  A61K38/36 ,  A61K2039/505 ,  A61P7/02 ,  A61P35/00 ,  A61P37/00 ,  C07K16/06 ,  C07K16/065 ,  C07K2317/21

摘要： The invention relates to a composition strongly enriched with anti-A and/or anti-B polyclonal immunoglobulins, comprising polyclonal human immunoglobulins, characterised in that at least 80 wt.-% of the polyclonal human immunoglobulins present in the composition are anti-A or anti-B polyclonal human immunoglobulins, for use as a drug, particularly in the treatment of polycythemia and/or autoimmune diseases, and in particular peripheral autoimmune thrombocytopenia.

公开(公告)号：US20180104318A1

公开(公告)日：2018-04-19

申请号：US15561690

申请日：2016-03-31

申请人： KYOWA HAKKO KIRIN CO., LTD.

发明人： Mayumi MUKAI

IPC分类号： A61K38/57 ,  A61K31/727 ,  A61K9/00 ,  A61P7/02

CPC分类号： A61K38/57 ,  A61K9/0019 ,  A61K31/727 ,  A61K38/55 ,  A61P7/02

摘要： The present invention pertains to a therapeutic composition comprising antithrombin gamma for diffuse intravascular coagulation or disseminated intravascular coagulation involving a decrease of antithrombin, or for thrombophilia due to congenital antithrombin deficiency.

公开(公告)号：US20170296629A1

公开(公告)日：2017-10-19

申请号：US15517008

申请日：2015-10-06

申请人： Hiroshi KAWAKAMI ,  KEIO UNIVERSITY ,  NRL PHARMA, INC.

发明人： Junichi HIRAHASHI ,  Koshu OKUBO ,  Hiroshi KAWAKAMI ,  Shinji KAGAYA

IPC分类号： A61K38/40 ,  A61K9/00

CPC分类号： A61K38/40 ,  A61K9/0019 ,  A61K9/0053 ,  A61K38/00 ,  A61P7/02 ,  A61P9/00 ,  A61P13/12 ,  A61P29/00 ,  A61P31/04 ,  A61P31/06 ,  A61P37/06 ,  C07K14/47

摘要： An object of the present invention is to provide a novel drug inhibiting extracellular trap formation in leukocytes. The present invention provides an inhibitor of extracellular trap formation in leukocytes containing a lactoferrin fragment, and a composition containing lactoferrin for treating a disease related to the extracellular trap formation in leukocytes.

公开(公告)号：US20170226225A1

公开(公告)日：2017-08-10

申请号：US15409607

申请日：2017-01-19

申请人： Merck Sharp & Dohme Corp.

发明人： Zhu Chen ,  Kenneth P. Ellsworth ,  James A. Milligan ,  Elizabeth Oldham ,  Dietmar Seiffert ,  Vaishnavi Ganti ,  Mohammad Tabrizifard

IPC分类号： C07K16/36 ,  C07K16/30

CPC分类号： C07K16/36 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/545 ,  A61P7/02 ,  C07K14/745 ,  C07K16/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.